- Home
- GBIO vs COEP Comparison
GBIO vs COEP Comparison
Compare GBIO & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GBIO
- COEP
- Stock Information
- Founded
- GBIO 2016
- COEP 2017
- Country
- GBIO United States
- COEP United States
- Employees
- GBIO N/A
- COEP N/A
- Industry
- GBIO Biotechnology: Pharmaceutical Preparations
- COEP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GBIO Health Care
- COEP Health Care
- Exchange
- GBIO Nasdaq
- COEP Nasdaq
- Market Cap
- GBIO 29.2M
- COEP 32.0M
- IPO Year
- GBIO 2020
- COEP N/A
- Fundamental
- Price
- GBIO $0.38
- COEP $7.66
- Analyst Decision
- GBIO Strong Buy
- COEP
- Analyst Count
- GBIO 4
- COEP 0
- Target Price
- GBIO $7.33
- COEP N/A
- AVG Volume (30 Days)
- GBIO 558.2K
- COEP 26.4K
- Earning Date
- GBIO 08-06-2025
- COEP 08-15-2025
- Dividend Yield
- GBIO N/A
- COEP N/A
- EPS Growth
- GBIO N/A
- COEP N/A
- EPS
- GBIO N/A
- COEP N/A
- Revenue
- GBIO $24,556,000.00
- COEP $62,874.00
- Revenue This Year
- GBIO N/A
- COEP N/A
- Revenue Next Year
- GBIO N/A
- COEP N/A
- P/E Ratio
- GBIO N/A
- COEP N/A
- Revenue Growth
- GBIO 146.47
- COEP N/A
- 52 Week Low
- GBIO $0.32
- COEP $2.31
- 52 Week High
- GBIO $3.65
- COEP $13.70
- Technical
- Relative Strength Index (RSI)
- GBIO 48.07
- COEP 33.94
- Support Level
- GBIO $0.35
- COEP $7.50
- Resistance Level
- GBIO $0.41
- COEP $8.62
- Average True Range (ATR)
- GBIO 0.03
- COEP 0.48
- MACD
- GBIO -0.00
- COEP -0.15
- Stochastic Oscillator
- GBIO 30.11
- COEP 3.77
About GBIO Generation Bio Co.
Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.